• Voluntarily join this study, sign the informed consent form, have good compliance, and be able to cooperate with the follow-up.

• Age 18\

⁃ 75 years old.

• Cytologically or histologically confirmed diagnosis of recurrent epithelial ovarian, fallopian tube, or primary peritoneum cancer.

• Patient has been previously treated with a platinum-containing regimen and has been treated with a platinum-based regimen during the last dose of platinum-based therapy (self-treatment initiation to within 1 month after the last dose) efficacy is non-PD, 6 months after the end of treatment (183 disease progression or recurrence within calendar days, and the number of lines of systemic therapy after platinum resistance ≤1 line.

• At least one measurable lesion per RECIST v1.1 criteria.

• ECOG PS score: 0-1 points.

• Expected survival period ≥ 3 weeks.

• Good level of organ function.

• Subjects of childbearing potential who need to use highly effective contraception from the time of signing informed to 210 days after the last dose of trial drug; Subjects of childbearing potential must have a negative serum HCG within 7 days prior to the first dose and must be non-lactating.